AGTC hopes to gain the first approval in X-linked retinitis pigmentosa for its gene therapy AGTC-501, now in a Phase II/III study. It also is advancing ...
https://www.google.com/url?rct=j&sa=t&url=https://scrip.pharmaintelligence.informa.com/SC144794/AGTC-Moves-Past-Biogen-With-Ophthalmic-Gene-Therapy&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNGwAEK9B6I6VMcoT9luXlf92ErL7A
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.